Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

Femasys Inc. announced it has doubled the number of actively enrolling sites in its FemBloc FINALE Pivotal Trial to twelve across the United States, including prominent academic centers like Baylor Research Institute and Columbia University Medical Center. The expansion, enabled by August 2026 financing, demonstrates progress in the company's U.S. regulatory strategy for FDA approval of FemBloc, a non-surgical permanent birth control solution already approved in Europe, UK, and New Zealand.